Decreased xanthine oxidoreductase is a predictor of poor prognosis in early‐stage gastric cancer

BACKGROUND: Xanthine oxidoreductase (XOR) is a key enzyme in the degradation of DNA, RNA and high‐energy phosphates. About half of the patients with breast cancer have a decrease in XOR expression. Patients with breast cancer with unfavourable prognosis are independently identified by the loss of XO...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Linder, N, Haglund, C, Lundin, M, Nordling, S, Ristimäki, A, Kokkola, A, Mrena, J, Wiksten, J‐P, Lundin, J
Format: Artigo
Langue:Inglês
Publié: BMJ Group 2006
Sujets:
Original Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC1860491/
https://ncbi.nlm.nih.gov/pubmed/16935971
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jcp.2005.032524
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires